NovoCure (NVCR) Piper Sandler 36th Annual Healthcare Conference summary

Key clinical milestones and timelines

• PANOVA-3 phase 3 trial in first-line pancreatic cancer met its primary endpoint, marking the first such success in this patient group.

• Regulatory submissions for the U.S., Europe, and Japan are expected within six months, with approval anticipated by mid-2026.

• Full data presentation is targeted for a major medical conference in the first half of 2026, with peer-reviewed publication planned in parallel.

• Pre-launch activities for the new indication will begin late 2024 or early 2025, with commercial launch immediately following approval.

Market opportunity and product expansion

• The initial target addressable market (TAM) for the new pancreatic indication is about 15,000 patients, roughly double the size of the current GBM market.

• PANOVA-4, a phase 2 trial for metastatic pancreatic cancer, has completed enrollment, with top-line data expected in early 2026.

• The company is also expanding into non-small cell lung cancer, with a recent U.S. approval and early launch activities underway.

Product innovation and business impact

• High-intensity arrays for GBM, now approved in the U.S., are lighter, thinner, and more comfortable, potentially improving patient compliance and therapy duration.

• The new array technology is expected to be incorporated into future launches for lung and pancreatic cancer indications.

• Product improvements support both patient outcomes and the extension of intellectual property protection.